NPX372 for Cancer

This trial tests a new treatment called NPX372, an antibody drug designed to help the immune system target and destroy cancer cells. Researchers focus on ensuring NPX372's safety and determining the best dose for future studies. The study seeks individuals with recurring or widespread solid tumors, such as certain types of lung or ovarian cancer, that have not responded to standard treatments. Participants will receive NPX372 through an IV infusion and undergo close monitoring by doctors.

As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have had systemic anti-cancer treatment within 10 days before starting the study, and certain other treatments have specific waiting periods. It's best to discuss your current medications with the trial team.

Research has shown that NPX372 has promising safety results from early studies. In preclinical trials, conducted in the lab before human testing, NPX372 was well-tolerated, meaning it did not cause serious side effects in the test models. It also effectively helped shrink tumors.

The studies indicate that NPX372 is safe at doses similar to those planned for humans. Importantly, there were no signs of cytokine release syndrome, a serious condition where the immune system overreacts.

Unlike the standard cancer treatments like chemotherapy and radiation, NPX372 is unique because it is administered intravenously over 60 minutes, offering a potentially more targeted approach. Researchers are excited about NPX372 because it may work differently by targeting specific cancer cells with its novel formulation, potentially reducing side effects associated with traditional treatments. This makes NPX372 a promising option in the fight against cancer, as it could offer a more precise and effective treatment.

Research has shown that NPX372, the investigational treatment in this trial, may help treat certain cancers. In lab studies, NPX372 activated immune cells called T cells, which then targeted and killed cancer cells with a specific protein, B7-H7, on their surface. In animal tests, NPX372 caused tumors to shrink completely and was well tolerated. These results suggest NPX372 could effectively enhance the body's immune response against tumors. Early findings also indicate it might slow tumor growth by affecting the formation of blood vessels around the tumor.¹³⁴⁶⁷